Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 1
2014 3
2015 5
2016 4
2017 1
2018 2
2019 3
2020 3
2021 7
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Pancreatic cancer in young adults: changes, challenges, and solutions.
Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D. Primavesi F, et al. Among authors: schlick k. Onco Targets Ther. 2019 May 6;12:3387-3400. doi: 10.2147/OTT.S176700. eCollection 2019. Onco Targets Ther. 2019. PMID: 31118690 Free PMC article. Review.
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Riedl JM, Schwarzenbacher E, Moik F, Horvath L, Gantschnigg A, Renneberg F, Posch F, Barth DA, Stotz M, Pichler M, Hatzl S, Fandler-Höfler S, Gressenberger P, Gary T, Jost PJ, Greil R, Ay C, Djanani A, Gerger A, Schlick K. Riedl JM, et al. Among authors: schlick k. Thromb Haemost. 2022 Apr;122(4):633-645. doi: 10.1055/a-1548-4847. Epub 2021 Aug 24. Thromb Haemost. 2022. PMID: 34255340
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Müller M, Posch F, Kiem D, Barth D, Horvath L, Stotz M, Schaberl-Moser R, Pichler M, Greil R, Jost PJ, Seeber A, Amann A, Schlick K, Gerger A, Riedl JM. Müller M, et al. Among authors: schlick k. Ther Adv Med Oncol. 2021 Sep 30;13:17588359211039930. doi: 10.1177/17588359211039930. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34616490 Free PMC article.
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, Moik F, Barth DA, Rossmann CH, Stotz M, Schaberl-Moser R, Pichler M, Stöger H, Greil R, Djanani A, Schlick K, Gerger A. Riedl JM, et al. Among authors: schlick k. Eur J Cancer. 2021 Jul;151:3-13. doi: 10.1016/j.ejca.2021.03.040. Epub 2021 May 2. Eur J Cancer. 2021. PMID: 33951545 Free article.
Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol.
Huemer F, Hecht S, Scharinger B, Schlintl V, Rinnerthaler G, Schlick K, Heregger R, Melchardt T, Wimmer A, Mühlbacher I, Koch OO, Neureiter D, Klieser E, Seyedinia S, Beheshti M, Greil R, Weiss L. Huemer F, et al. Among authors: schlick k. J Cancer Res Clin Oncol. 2023 Jul;149(7):3051-3064. doi: 10.1007/s00432-022-04096-w. Epub 2022 Jul 21. J Cancer Res Clin Oncol. 2023. PMID: 35864270 Free PMC article.
34 results